Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00407745 · ClinicalTrials.gov registry record · Phase 3

A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury

A Phase 3 study of Spinal Cord Injuries and Neuralgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

Completed
Registry status
Phase 3
Development phase
220
Enrollment target
20
Study locations

NCT00407745 is a Phase 3 study of Spinal Cord Injuries and Neuralgia that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 220 participants, above the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (261% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00407745, a Phase 3 study of Spinal Cord Injuries and Neuralgia, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

COMPLETED
Registry status
Phase 3
Development phase
220 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate if pregabalin relieves nerve pain associated with spinal cord injury compared to placebo (pill that contains no active medicine). This study will also evaluate the safety of pregabalin in this patient population.

Conditions Studied

Spinal Cord Injuries Neuralgia

Interventions

  • DRUG placebo
  • DRUG pregabalin

Study Locations (20)

California

  • Pfizer Investigational Site - Fresno
  • Pfizer Investigational Site - Napa
  • Pfizer Investigational Site - Northridge
  • Pfizer Investigational Site - Pasadena

Arizona

  • Pfizer Investigational Site - Phoenix
  • Pfizer Investigational Site - Phoenix
  • Pfizer Investigational Site - Phoenix

Florida

  • Pfizer Investigational Site - Miami
  • Pfizer Investigational Site - Miami
  • Pfizer Investigational Site - Orlando

New York

  • Pfizer Investigational Site - New York
  • Pfizer Investigational Site - White Plains

Pennsylvania

  • Pfizer Investigational Site - Johnstown
  • Pfizer Investigational Site - Philadelphia

Indiana

  • Pfizer Investigational Site - Indianapolis

Kansas

  • Pfizer Investigational Site - Overland Park

Michigan

  • Pfizer Investigational Site - Detroit

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2007-01
Est. Completion 2011-02
Phase Phase 3

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris

158 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00407745

The ClinicalTrials.gov registry entry for NCT00407745 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (261% higher). The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Spinal Cord Injuries appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00407745 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT00407745 about?

NCT00407745 is a clinical study titled "A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury". The purpose of this study is to evaluate if pregabalin relieves nerve pain associated with spinal cord injury compared to placebo (pill that contains no active medicine). This study will also evaluate the safety of pregabalin in this patient population.

What is the current status of trial NCT00407745?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2007-01. Estimated completion is 2011-02.

What conditions does trial NCT00407745 study?

This clinical trial studies the following conditions: Spinal Cord Injuries, Neuralgia.

What interventions are being tested in trial NCT00407745?

The interventions under investigation include: placebo (DRUG), pregabalin (DRUG).

Who is sponsoring clinical trial NCT00407745?

This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00407745 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Spinal Cord Injuries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Spinal Cord Injuries

All registered trials for this condition

Neuralgia

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.